# Tissue Transglutaminase Test Market

> Tissue Transglutaminase Test Market: By Type (Serological, Biopsy, and others), and By End Users (Hospitals & Clinics, Homecare, Research Organisations, others) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.98%
- **2024:** $ 6.31 Billion
- **2025:** $ 7.5 Billion
- **2035:** $ 42.65 Billion
- **Key Players:** Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), QuidelOrtho Corporation (US), Hoffmann-La Roche (CH), Genova Diagnostics (US)

**Report ID:** MRFR/LS/0328-HCR · **Pages:** 81 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/tissue-transglutaminase-test-market-824

---

## Market Summary

As per Market Research Future analysis, the Tissue Transglutaminase Test Market Size was estimated at 6.306 USD Billion in 2024. The Tissue Transglutaminase Test industry is projected to grow from 7.503 USD Billion in 2025 to 42.65 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 18.98% during the forecast period 2025 - 2035

## Market Drivers

### Regulatory Support and Guidelines

Regulatory support and the establishment of guidelines for the diagnosis of celiac disease are crucial factors driving the Tissue Transglutaminase Test Market. Health authorities are increasingly recognizing the importance of standardized testing protocols, which enhances the credibility and acceptance of tissue transglutaminase tests. These guidelines not only facilitate accurate diagnosis but also promote the integration of these tests into clinical practice. As regulatory bodies continue to endorse the use of tissue transglutaminase tests, healthcare providers are more likely to adopt them, leading to a projected increase in market growth. The Tissue Transglutaminase Test Market is anticipated to expand as a result of these supportive measures.

### Shift Towards Preventive Healthcare

The ongoing shift towards preventive healthcare is influencing the Tissue Transglutaminase Test Market in notable ways. As healthcare systems worldwide emphasize early detection and prevention of diseases, the demand for diagnostic tests, including tissue transglutaminase tests, is on the rise. This trend is supported by a growing body of evidence linking early diagnosis of celiac disease to improved patient outcomes. Consequently, healthcare providers are increasingly recommending these tests as part of routine screenings, particularly for individuals with risk factors. The Tissue Transglutaminase Test Market is projected to benefit from this preventive approach, with an expected increase in test utilization by approximately 15% over the next few years.

### Increased Awareness of Celiac Disease

The rising awareness of celiac disease among the general population is a pivotal driver for the Tissue Transglutaminase Test Market. Educational campaigns and advocacy from health organizations have significantly contributed to the understanding of this autoimmune disorder. As more individuals recognize the symptoms and seek diagnosis, the demand for tissue transglutaminase tests is likely to increase. Recent surveys indicate that nearly 1 in 100 individuals are affected by celiac disease, yet many remain undiagnosed. This gap presents a substantial opportunity for growth within the Tissue Transglutaminase Test Market, as healthcare providers strive to meet the needs of an informed patient population.

### Rising Incidence of Autoimmune Disorders

The increasing incidence of autoimmune disorders, including celiac disease, is a significant driver for the Tissue Transglutaminase Test Market. Research indicates that autoimmune diseases are on the rise, with celiac disease being one of the most prevalent. This trend is likely attributed to various factors, including environmental influences and genetic predispositions. As more individuals are diagnosed with autoimmune conditions, the demand for specific diagnostic tests, such as tissue transglutaminase tests, is expected to grow. The Tissue Transglutaminase Test Market may see a compound annual growth rate of around 7% as healthcare systems adapt to the rising need for accurate and timely diagnostics.

### Technological Advancements in Testing Methods

The Tissue Transglutaminase Test Market is experiencing a surge in technological advancements that enhance the accuracy and efficiency of testing methods. Innovations such as automated testing systems and high-throughput screening techniques are streamlining the diagnostic process. These advancements not only reduce the time required for test results but also improve the reliability of the tests. As a result, healthcare providers are increasingly adopting these modern technologies, leading to a projected growth rate of approximately 8% in the Tissue Transglutaminase Test Market over the next five years. Furthermore, the integration of artificial intelligence in data analysis is expected to refine diagnostic capabilities, making it easier for clinicians to identify celiac disease and related disorders.

## Future Outlook

The Tissue Transglutaminase Test Market is projected to grow at an 18.98% CAGR from 2025 to 2035, driven by increasing celiac disease diagnoses and advancements in diagnostic technologies.

**New opportunities:**

- Development of point-of-care testing devices for rapid diagnosis. Expansion into emerging markets with tailored marketing strategies. Partnerships with healthcare providers for integrated testing solutions.

By 2035, the market is expected to solidify its position as a leader in diagnostic testing.

## Segment Insights

### By Type: Serological Testing (Largest) vs. Biopsy (Fastest-Growing)

The Tissue Transglutaminase Test Market is primarily segmented into three types: Serological Testing, Biopsy, and Others. Among these, Serological Testing holds the largest share, attributed to its widespread adoption due to ease of use and accuracy in diagnosing [celiac disease](https://www.marketresearchfuture.com/reports/celiac-disease-treatment-market-8474) and gluten sensitivity. Biopsy, although smaller in market share, is rapidly gaining traction as it provides definitive diagnosis, showing significant growth in its implementation across various healthcare settings. The 'Others' category encompasses alternative testing methods that remain niche but are witnessing a gradual increase in popularity based on innovative methodologies.

Serological Testing (Dominant) vs. Biopsy (Emerging)

Serological Testing is regarded as the dominant modality in the Tissue Transglutaminase Test Market due to its non-invasive nature and high sensitivity for detecting tissue transglutaminase antibodies, making it a preferred choice among clinicians. In contrast, the Biopsy segment is emerging as a critical diagnostic tool, particularly in complex cases where serology results might be inconclusive. Biopsy provides histological evidence, reinforcing its necessity in precise diagnoses. Both segments are essential, but while Serological Testing is driving volume and convenience, Biopsy’s growth highlights a shift towards comprehensive diagnostic approaches in the field of autoimmune disorders.

### By End User: Clinics and Hospitals (Largest) vs. Home Care (Fastest-Growing)

The Tissue Transglutaminase Test Market demonstrates a significant distribution across various end-user segments, with Clinics and Hospitals leading the way. This segment captures a substantial portion of the market share due to the high number of diagnostic procedures performed in these settings. On the other hand, the Home Care segment is gaining momentum, driven by the growing preference for at-home diagnostic solutions that enhance patient convenience and comfort. Research Organizations and Others also contribute to the market but at a relatively smaller scale.

End User: Clinics and Hospitals (Dominant) vs. Home Care (Emerging)

Clinics and Hospitals play a dominant role in the Tissue Transglutaminase Test Market, providing essential diagnostic services and facilitating timely patient care for gluten-related disorders. Their established infrastructure and accessibility ensure a steady demand for these tests. Meanwhile, the Home Care segment emerges as a significant player, catering to the increasing inclination of patients to manage their health conditions from the comfort of their homes. This trend is bolstered by advancements in home-testing kits that deliver reliable results, fostering greater autonomy for patients and reducing the burden on healthcare facilities. The balance between these segments reflects evolving patient preferences and the broader shifts in healthcare delivery.

## Regional Market Share Analysis

### North America : Leading Market for Diagnostics

North America is the largest market for Tissue Transglutaminase tests, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of celiac disease, advancements in diagnostic technologies, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for diagnostic tests, further boosting market demand. The United States is the primary contributor, with significant investments in healthcare infrastructure and research. Key players such as Thermo Fisher Scientific and Abbott Laboratories are leading the market, focusing on innovative solutions and expanding their product portfolios. The competitive landscape is characterized by collaborations and partnerships aimed at enhancing diagnostic accuracy and accessibility.

### Europe : Emerging Market with Growth Potential

Europe is the second-largest market for Tissue Transglutaminase tests, holding around 30% of the global market share. The region's growth is fueled by rising awareness of autoimmune diseases, increasing healthcare expenditure, and favorable regulatory frameworks. The European Medicines Agency (EMA) has been proactive in promoting innovative diagnostic solutions, which is expected to enhance market growth. Leading countries include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced diagnostic technologies. Major players like Roche Diagnostics and Siemens Healthineers are investing in research and development to meet the growing demand. The competitive landscape is marked by a focus on quality and regulatory compliance, ensuring that products meet stringent European standards.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is witnessing rapid growth in the Tissue Transglutaminase test market, contributing approximately 20% to the global market share. The region's expansion is driven by increasing healthcare investments, a growing population, and rising incidences of celiac disease. Governments are implementing policies to improve healthcare access, which is further propelling market growth. Countries like China, India, and Japan are leading the market, with significant investments in healthcare infrastructure and technology. The competitive landscape features both local and international players, including Bio-Rad Laboratories and Ortho Clinical Diagnostics, who are focusing on expanding their market presence through strategic partnerships and product innovations. The region is becoming a hub for diagnostic advancements, catering to the increasing demand for accurate testing solutions.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually emerging in the Tissue Transglutaminase test market, holding about 5% of the global market share. Growth is driven by increasing awareness of celiac disease and improvements in healthcare infrastructure. However, challenges such as limited access to advanced diagnostic technologies and varying regulatory environments hinder faster growth. Governments are working to enhance healthcare systems, which is expected to positively impact market dynamics. Leading countries include South Africa and the UAE, where there is a growing focus on improving healthcare services. The competitive landscape is characterized by a mix of local and international players, with companies like QuidelOrtho Corporation making strides in expanding their reach. The market is poised for growth as investments in healthcare continue to rise, addressing the needs of the population.

## Competitive Benchmarking

The Tissue Transglutaminase Test Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of celiac disease and the growing demand for accurate diagnostic tools. Major players such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Roche Diagnostics (CH) are strategically positioned to leverage their extensive research capabilities and innovative product offerings. These companies are focusing on enhancing their diagnostic accuracy and expanding their market reach through strategic partnerships and technological advancements. The collective efforts of these key players are shaping a competitive environment that emphasizes innovation and responsiveness to market needs.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set industry standards and drive technological advancements. This competitive structure suggests that while there is room for smaller players, the dominance of established firms is likely to continue shaping market dynamics.

In August 2025, Abbott Laboratories (US) announced the launch of a new, highly sensitive tissue transglutaminase test that significantly reduces the time required for diagnosis. This innovation is expected to enhance patient outcomes by facilitating earlier detection of celiac disease. The strategic importance of this launch lies in Abbott's commitment to maintaining its leadership position in the diagnostics market, particularly in the realm of autoimmune diseases, where timely intervention is crucial.

In September 2025, Roche Diagnostics (CH) expanded its product portfolio by acquiring a small biotech firm specializing in advanced diagnostic technologies. This acquisition is likely to bolster Roche's capabilities in the tissue transglutaminase testing space, allowing for the integration of cutting-edge technologies into their existing offerings. Such strategic moves indicate Roche's focus on innovation and its intent to remain competitive in a rapidly evolving market.

In July 2025, Thermo Fisher Scientific (US) entered into a strategic partnership with a leading healthcare provider to enhance the accessibility of its tissue transglutaminase tests in underserved regions. This collaboration aims to improve diagnostic services and expand market penetration, particularly in areas with limited access to advanced healthcare solutions. The partnership underscores Thermo Fisher's commitment to addressing healthcare disparities while simultaneously driving growth in its diagnostic segment.

As of October 2025, current competitive trends in the Tissue Transglutaminase Test Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence in diagnostic processes. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver rapid, accurate diagnostic solutions.

## Recent News & Developments

**Report**

To gain a deeper insight into the market, and industry performance, Market Research Future's report on Tissue Transglutaminase Test Market provides extensive primary research along with a detailed analysis of both the qualitative and quantitative aspects by various industry experts. An in-depth analysis of the market is provided in this report which covers historical and projected Tissue transglutaminase test market sizes in terms of volume and value, technological advancements, macroeconomics, and governing factors. In the report, the top key players in the industry are detailed and their strategies are outlined. 

There is also a comprehensive analysis of market segments and regions included in the report. It also gives a detailed analysis for investors to make informed decisions and also analyzes which part of the market will be the most fruitful for an investment decision to be made. The report also skims down the growth and restraints that let us the information on the Tissue transglutaminase Test Market growth.

This report is a great opportunity for the Tissue transglutaminase (TTG) Test Market key trends and also a global analysis for Tissue transglutaminase Test Market Value to understand the nitty-gritty of the market.

## Report Scope

| MARKET SIZE 2024 | 6.306(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.503(USD Billion) |
| MARKET SIZE 2035 | 42.65(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.98% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), QuidelOrtho Corporation (US), Hoffmann-La Roche (CH), Genova Diagnostics (US) |
| Segments Covered | Type, End Users |
| Key Market Opportunities | Advancements in diagnostic technologies enhance accuracy and accessibility in the Tissue Transglutaminase Test Market. |
| Key Market Dynamics | Rising demand for accurate celiac disease diagnosis drives innovation and competition in the Tissue Transglutaminase Test market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Tissue Transglutaminase Test Market by 2035?**
A: The projected market valuation for the Tissue Transglutaminase Test Market is expected to reach 42.65 USD Billion by 2035.

**Q: What was the market valuation for the Tissue Transglutaminase Test Market in 2024?**
A: The market valuation for the Tissue Transglutaminase Test Market was 6.306 USD Billion in 2024.

**Q: What is the expected CAGR for the Tissue Transglutaminase Test Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Tissue Transglutaminase Test Market during the forecast period 2025 - 2035 is 18.98%.

**Q: Which companies are considered key players in the Tissue Transglutaminase Test Market?**
A: Key players in the Tissue Transglutaminase Test Market include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.

**Q: What are the main segments of the Tissue Transglutaminase Test Market?**
A: The main segments of the Tissue Transglutaminase Test Market include Serological Testing, Biopsy, and Others.

**Q: How did the Serological Testing segment perform in 2024?**
A: In 2024, the Serological Testing segment was valued at 2.5 USD Billion.

**Q: What is the projected value of the Home Care segment by 2035?**
A: The Home Care segment is projected to reach a value of 8.5 USD Billion by 2035.

**Q: What was the valuation of the Biopsy segment in 2024?**
A: The Biopsy segment was valued at 2.0 USD Billion in 2024.

**Q: How does the market for Clinics and Hospitals compare to other end users?**
A: The market for Clinics and Hospitals was valued at 2.52 USD Billion in 2024, indicating a strong position compared to other end users.

**Q: What is the expected growth trend for the Tissue Transglutaminase Test Market?**
A: The Tissue Transglutaminase Test Market is expected to experience robust growth, driven by an anticipated CAGR of 18.98% from 2025 to 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/tissue-transglutaminase-test-market-824*